The global gastric cancer drugs market size reached US$ 4.6 Billion in 2023. Looking forward, the market is projected to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 11.75% during 2023-2032. The rising prevalence of chronic and acute indications, growing incidences of weight-related health concerns, and increasing health consciousness represent some of the key factors driving the market.
Gastric cancer drugs are medications developed to relieve or treat an individual diagnosed with stomach cancer in which malignant cells form in the lining of the stomach. Some common symptoms of gastric cancer are unexplained weight loss, indigestion, bloating, nausea, vomiting, heartburn, and difficulty swallowing food. Doxorubicin hydrochloride, sunitinib, mitomycin, fluorouracil, imatinib, and docetaxel are commonly available gastric cancer drugs. They help to shrink a tumor and relieve signs and symptoms of cancer by killing some of the cancer cells. They also assist in reducing cancer cells from growing, dividing, and making more cells. As a result, gastric cancer drugs are administered through oral and parenteral forms and are used by hospitals, clinics, and special treatment centers.
The increasing geriatric population and the rising prevalence of obesity across the globe are primarily driving the market growth. In line with this, the growing incidences of weight-related health concerns due to unhealthy eating habits and sedentary lifestyles are favoring the market growth. Moreover, the increasing cases of cancer, due to the rising consumption of tobacco-based products and alcoholic beverages, and the enhanced need need for preventive and therapeutic medications are acting as another growth-inducing factor. Apart from this, the introduction of two gastric cancer biomarkers that help in eliminating tumor growth is providing an impetus to the market growth.
Moreover, manufacturers are focusing on creating product variants with minimal side effects, such as gastric erosion and nausea, thus propelling the market toward growth. Along with this, rapid technological advancements focusing on the development of effective and specific cancer treatments are creating a positive outlook for the market. Furthermore, leading pharmaceutical companies and key players are investing heavily in research and development (R&D) activities to develop gastric cancer drugs that are safer, more effective, economically viable, and easier to administer.
Besides this, the implementation of various government initiatives to promote the manufacturing, processing, and packing of a drug product ensuring the quality of drugs produced by manufacturers is positively influencing the market growth. Other factors, including rising healthcare expenditure and growing consumer awareness regarding the symptoms and the available treatment options for gastric cancer, are anticipated to drive the market growth.
Gastric cancer drugs are medications developed to relieve or treat an individual diagnosed with stomach cancer in which malignant cells form in the lining of the stomach. Some common symptoms of gastric cancer are unexplained weight loss, indigestion, bloating, nausea, vomiting, heartburn, and difficulty swallowing food. Doxorubicin hydrochloride, sunitinib, mitomycin, fluorouracil, imatinib, and docetaxel are commonly available gastric cancer drugs. They help to shrink a tumor and relieve signs and symptoms of cancer by killing some of the cancer cells. They also assist in reducing cancer cells from growing, dividing, and making more cells. As a result, gastric cancer drugs are administered through oral and parenteral forms and are used by hospitals, clinics, and special treatment centers.
The increasing geriatric population and the rising prevalence of obesity across the globe are primarily driving the market growth. In line with this, the growing incidences of weight-related health concerns due to unhealthy eating habits and sedentary lifestyles are favoring the market growth. Moreover, the increasing cases of cancer, due to the rising consumption of tobacco-based products and alcoholic beverages, and the enhanced need need for preventive and therapeutic medications are acting as another growth-inducing factor. Apart from this, the introduction of two gastric cancer biomarkers that help in eliminating tumor growth is providing an impetus to the market growth.
Moreover, manufacturers are focusing on creating product variants with minimal side effects, such as gastric erosion and nausea, thus propelling the market toward growth. Along with this, rapid technological advancements focusing on the development of effective and specific cancer treatments are creating a positive outlook for the market. Furthermore, leading pharmaceutical companies and key players are investing heavily in research and development (R&D) activities to develop gastric cancer drugs that are safer, more effective, economically viable, and easier to administer.
Besides this, the implementation of various government initiatives to promote the manufacturing, processing, and packing of a drug product ensuring the quality of drugs produced by manufacturers is positively influencing the market growth. Other factors, including rising healthcare expenditure and growing consumer awareness regarding the symptoms and the available treatment options for gastric cancer, are anticipated to drive the market growth.
Key Market Segmentation
This report provides an analysis of the key trends in each segment of the global gastric cancer drugs market, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on type, route of administration, and end user.Type Insights
- Doxorubicin Hydrochloride
- Sunitinib
- Docetaxel
- Mitomycin
- Fluorouracil
- Imatinib
- Trastuzumab
Route of Administration Insights
- Oral
- Parenteral
End User Insights
- Hospitals
- Clinics
- Others
Regional Insights
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global gastric cancer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Arog Pharamaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
- How has the global gastric cancer drugs market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global gastric cancer drugs market?
- What are the key regional markets?
- Which countries represent the most attractive gastric cancer drugs market?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on end user?
- What is the competitive structure of the global gastric cancer drugs market?
- Who are the key players/companies in the global gastric cancer drugs market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Gastric Cancer Drugs Market
6 Market Breakup by Type
7 Market Breakup by Route of Administration
8 Market Breakup by End User
9 Market Breakup by Region
10 Drivers, Restraints, and Opportunities
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Arog Pharamaceuticals Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Ono Pharmaceutical Co. Ltd.
- Sanofi S.A.
- Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 4.6 Billion |
| Forecasted Market Value ( USD | $ 12.5 Billion |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
